Organization
China National Biotec Group
10 clinical trials
92 abstracts
Clinical trial
A Randomized, Blinded, Parallel Controlled Phase 3 Clinical Study to Evaluate the Safety and Immunogenicity of the Diphtheria, Tetanus and Three-components Acellular Pertussis Combined Vaccine, Adsorbed in Healthy Infants at the Age of 2 Months and 3 MonthsStatus: Active (not recruiting), Estimated PCD: 2023-09-22
Clinical trial
A Study to Evaluate the Safety and Immunogenicity of Omicron COVID-19 Vaccine (Vero Cell), Inactivated in Population 18 Years Old of Age and Above With no Vaccination History of COVID-19 VaccineStatus: Active (not recruiting), Estimated PCD: 2023-10-01
Clinical trial
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of Live Attenuated Varicella Vaccine in Healthy PeopleStatus: Active (not recruiting), Estimated PCD: 2024-04-14
Clinical trial
A Immunobridging and Immunization Schedules Study of COVID-19 Vaccine (Vero Cell), Inactivated in Population Aged ≥ 60 Years Old and 3-17 Years Old Compared With That in Population Aged 18-59 Years OldStatus: Active (not recruiting), Estimated PCD: 2021-12-20
Clinical trial
Immunogenicity Non-inferiority Immuno-bridging Study of Inactivated SARS-CoV-2 Vaccine in Healthy Population Aged 3-17 Years Old vs Healthy Population Aged 18 Years Old and AboveStatus: Completed, Estimated PCD: 2022-03-31
Clinical trial
A Single-center, Randomized, Double-blind Trial to Evaluate the Lot-to-lot Consistency of Live Attenuated Varicella Vaccine in Healthy People 1-12 Years of AgeStatus: Active (not recruiting), Estimated PCD: 2023-07-30
Clinical trial
A Randomized, Controlled, Multicenter Phase 4 Clinic Trial to Evaluate the Safety and Immunogenicity of Simultaneously Administration of EV71 Vaccine and Influenza Vaccine (Split Virion),InactivatedStatus: Completed, Estimated PCD: 2020-01-06
Clinical trial
Multicenter, Randomized, Double Blind, Parallel Placebo Controlled, Phase III Clinical Trial to Evaluate the Protective Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) in Healthy Population Aged 18 Years Old and AboveStatus: Completed, Estimated PCD: 2021-06-16
Clinical trial
A Randomized, Double-Blinded, Cohort Clinical Study on Evaluating the Safety and Immunogenicity of Sequential Immunization of Two Doses of BIBP Inactivated COVID-19 Vaccine (Omicron), WIBP Inactivated COVID-19 Vaccine (Omicron) or Inactivated COVID-19 Vaccine (Prototype) in Population Aged 18 Years and Above Who Have Completed Two or Three Doses of Inactivated or mRNA VaccineStatus: Active (not recruiting), Estimated PCD: 2023-07-27
Clinical trial
Safety and Immunogenicity Study on Omicron Inactivated COVID-19 Vaccine and Prototype Inactivated COVID-19 Vaccine in Population Aged 18 Years Old and Above Vaccinated the Prototype Inactivated COVID-19 VaccineStatus: Active (not recruiting), Estimated PCD: 2022-09-25
Abstract
BL-B01D1, a first-in-class EGFRxHER3 bispecific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic solid tumor: Results from a first-in-human phase 1 study.Org: Department of Medical Oncology, State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Collaborative Innovation Center for Cancer Medicine, Guangzhou JOYO Pharma, China National Biotec Group, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy,
Abstract
Randomized phase 3 study of first-line AZD3759 (zorifertinib) versus gefitinib or erlotinib in EGFR-mutant (EGFRm+) non–small-cell lung cancer (NSCLC) with central nervous system (CNS) metastasis.Org: Guangdong Lung Cancer Institute, China National Biotec Group, Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences), Guangzhou JOYO Pharma, Cancer Hospital,
Abstract
HER2-low status discordance between primary and recurrent/metastatic breast cancer in a large-scale cohort.Org: Fudan University Shanghai Cancer Center, China National Biotec Group, West China Hospital, Chengdu Origen Biotechnology, Department of Preventive Medicine,
Abstract
High-dose almonertinib in treatment-naïve EGFR-mutated NSCLC with CNS metastases: Efficacy and biomarker analysis.Org: Zhejiang Cancer Hospital, Hangzhou Yirui Pharmaceutical Technology, China National Biotec Group, Zhejiang Hospital, Department of Thoracic Medical Oncology,
Abstract
Neoadjuvant dalpiciclib, exemestane, and goserelin in premenopausal women with HR-positive, HER2-negative breast cancer: A prospective, multicenter, randomized two-group, non-controlled phase 2 clinical trial.Org: Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin Hemay Pharmaceutical, China National Biotec Group, Tianjian,
Abstract
Development and validation of point-of-care mobile solution to guide the diagnosis of malnutrition: A multicenter, prospective cohort study.Org: West China Hospital, Chengdu Origen Biotechnology, China National Biotec Group, Sichuan University,
Abstract
Association between comorbidity clusters and mortality in patients with cancer: A machine learning analysis of data from the US National Health and Nutrition Examination Survey 1999–2018.Org: School of Pharmacy and Pharmaceutical Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong Sanatorium & Hospital, China National Biotec Group,
Abstract
Unveiling the interplay of social factors in cancer survivorship: A comprehensive social determinants of health (SDOH) profile analysis.Org: Tsinghua University, Beijing InnoCare Pharma Tech, China National Biotec Group, University of Oklahoma Health Sciences Center, Oklahoma City,
Abstract
The TAC-GReD trial: The combination of talazoparib and carboplatin in DNA damage repair deficient recurrent high-grade glioma.Org: Department of Clinical Oncology, Queen Elizabeth Hospital, LKS Faculty of Medicine, University of Hong Kong, Department of Neurosurgery, Prince of Wales Hospital, Prince of Wales Hospital,
Abstract
Detection of TROP2: Ushering in a new choice in the treatment of patients with special types of invasive breast cancer.Org: Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, The Fourth Hospital of Hebei Medical University, Shijiazhuang Yiling Pharmaceutical, China National Biotec Group,
Abstract
Long-term outcomes of ablation versus surgery in patients with colorectal lung oligometastasis: A retrospective cohort study.Org: Sun Yat-sen University Cancer Center Gansu Hospital, Guangzhou JOYO Pharma, China National Biotec Group,
Abstract
Efficacy and safety of bronchial arterial chemoembolization (BACE) in combination with tislelizumab for non-small cell lung cancer (NSCLC): A phase II study.Org: The First Affiliated Hospital of Zhengzhou University, Zhengzhou Gensciences, China National Biotec Group,
Abstract
A single-arm, phase II trial assessing the combination of AK105 and anlotinib in first-line treatment for persistent, recurrent, or metastatic cervical cancer.Org: The First Affiliated Hospital of Zhengzhou University, Zhengzhou Gensciences, China National Biotec Group,
Abstract
Identification of molecular subtypes for integrated multi-omics analysis for use in guiding precision medicine in hepatocellular carcinoma.Org: Xiangya Hospital of Central South University, Changsha, China, Changsha, Hunan Center hospital, China National Biotec Group,
Abstract
Effect of immune checkpoint inhibitor administration timing on survival outcomes in advanced biliary tract cancers: A single-center propensity score matching analysis.Org: West China Hospital, Sichuan University, Chengdu Origen Biotechnology, Sichuan Baili Pharmaceutical, China National Biotec Group,
Abstract
Exploratory phase I study of HF1K16 for the treatment of patients with refractory/recurrent advanced glioma: Preliminary efficacy and mechanism as a monotherapy.Org: Huashan Hospital Fudan University, Fudan University (Xiamen Branch), Shanghai Henlius Biotech, China National Biotec Group, Zhejiang University, Hangzhou, China,
Abstract
A retrospective analysis of efficacy and safety of lenvatinib combined with PD-1 inhibitor and chemotherapy in advanced biliary tract cancer (BTC).Org: The Fifth Medical Center of PLA General Hospital, Beijing InnoCare Pharma Tech, China National Biotec Group,
Abstract
The tumor immune profile of bladder cancer (BC) with HER2 over-expression and the investigation into RC48-ADC versus BCG in high-risk non-muscle invasive BC with HER2 over-expression.Org: Department of Urology, Jinling Hospital, Clinical School of Medical College, Nanjing University, Nanjing, China, Institute of Urology, West China Hospital, Sichuan University, Chengdu Origen Biotechnology,
Abstract
First-in-human phase 1 study of SPH4336, a novel cyclin-dependent kinase 4/6 inhibitor, in patients with advanced solid tumors.Org: Cancer Center, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China, West China Hospital, Sichuan University, Chengdu Origen Biotechnology, China National Biotec Group,
Abstract
Non-invasive diagnosis of nature of pulmonary nodules using the whole genome methylation sequencing of circulating cell-free DNA.Org: State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center Gansu Hospital, Guangzhou JOYO Pharma,
Abstract
Maintenance treatment with toripalimab and anlotinib after anthracycline-based chemotherapy in patients with advanced soft tissue sarcoma (TORAN): A single-arm, phase 2 trial.Org: Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Cancer Center, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China, West China Hospital, Sichuan University, Chengdu Origen Biotechnology,
Abstract
A multi-center retrospective study on the efficacy and safety of regorafenib plus immune checkpoint inhibitors with or without TACE as a second-line treatment for advanced hepatocellular carcinoma.Org: Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Jinan, Shandong, China, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong Suncadia Medicine, China National Biotec Group,
Abstract
Single-cell landscape of the immune microenvironment of leptomeningeal metastases in non-small cell lung cancer treated with pemetrexed sheath injection.Org: Fujian Cancer Hospital, Fuzhou University, Fujian Shengdi Pharmaceutical, China National Biotec Group,
Abstract
Efficacy and safety of surufatinib, toripalimab, nab-paclitaxel in combination with radiotherapy or surgery in the first-line treatment of esophageal squamous cell cancer: A single-centered prospective clinical trial.Org: Chinese PLA General Hospital, Beijing InnoCare Pharma Tech, China National Biotec Group,
Abstract
Precision oncology and AI: The ACMA system for personalized treatment matching using real-world data.Org: OrigiMed, Shanghai Henlius Biotech, China National Biotec Group,
Abstract
A phase II trial of anlotinib combined chemotherapy as second-line and above therapy in HER2-negative advanced breast cancer.Org: Jiangsu Cancer Hospital, Nanjing Yoko Biomedical, Jiangsu HengRui Medicine, China National Biotec Group, The Affiliated Cancer Hospital of Nanjing Medical University,
Abstract
First-in-human phase 1 trial of the safety, tolerability, pharmacokinetics of BY101298: Initial report from dose escalation cohort.Org: Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Jinan, Shandong, China, Shandong University of Traditional Chinese Medicine Affiliated Hospital, Jinan, China National Biotec Group, Shandong Suncadia Medicine,
Abstract
Stereotactic body radiation therapy combined with atezolizumab and bevacizumab for hepatocellular carcinoma with extrahepatic metastasis: Preliminary result of a single-arm study.Org: Fudan University Shanghai Cancer Center, Shanghai Henlius Biotech, China National Biotec Group,
Abstract
Neoadjuvant chemoimmunotherapy in patients with limited-stage small cell lung cancer: A retrospective study.Org: Department of Thoracic Surgery and Lung Cancer Center, West China Hospital, Sichuan University, Chengdu Origen Biotechnology, China National Biotec Group,
Abstract
Effects of nursing intervention based on gratitude extension-construction theory on gratitude level, recurrence fear and post-traumatic growth of patients with breast cancer after surgery.Org: The First Affiliated Hospital of Nanjing Medical University, Nanjing, China, Nanjing Yoko Biomedical, China National Biotec Group,
Abstract
Transarterial chemoembolization (TACE) combined with donafenib as first-line therapy for unresectable hepatocellular carcinoma (uHCC): A real-world clinical study.Org: The First Affiliated Hospital of USTC, Anhui Provincial Hospital, Hefei, China, Sun Yat-sen University Cancer Center Gansu Hospital, Guangzhou JOYO Pharma, China National Biotec Group,
Abstract
Economic analysis of combined multi-cancer detection blood test and usual care.Org: Zhongshan Hospital of Fudan University, Shanghai, China, Fudan University (Xiamen Branch), Shanghai Henlius Biotech, China National Biotec Group, Burning Rock Biotech, Guangzhou, China,
Abstract
The safety and efficacy of immune checkpoint inhibitor in combination with FOLFOX as neoadjuvant/adjuvant therapy in patients with locally advanced colon cancer.Org: Xiangya Hospital of Central South University, Changsha, China, Changsha, China National Biotec Group, Central South University, Hunan Center hospital,
Abstract
Neoadjuvant chemoradiotherapy (nCRT) combined with sequential tislelizumab for resectable esophageal squamous cell carcinoma (ESCC): Preliminary results of a single-arm, open-label phase Ib trial (CRIS).Org: Zhejiang Cancer Hospital, Chinese Academy of Sciences, Hangzhou Yirui Pharmaceutical Technology, China National Biotec Group, Zhejing Cancer Hospital,
Abstract
Induction chemotherapy with nab-paclitaxel plus nedaplatin plus concurrent chemoradiotherapy in locally advanced nasopharyngeal carcinoma: A retrospective real-world study.Org: Zhejiang Cancer Hospital, Chinese Academy of Sciences, Hangzhou Yirui Pharmaceutical Technology, Zhejiang ACEA Pharmaceutical, China National Biotec Group,
Abstract
Hepatic artery infusion of FOLFOX chemotherapy and camrelizumab combined with sorafenib for advanced stage hepatocellular carcinoma (Double-IA-001): A phase II trial.Org: Sun Yat-sen University Cancer Center Gansu Hospital, Guangzhou JOYO Pharma, China National Biotec Group,
Abstract
Early detection, clinicopathological subtyping and prognosis prediction for patients with endometrial cancer using fragmentoimcs-based liquid-biopsy assay.Org: Department of Gynecologic Oncology, Gynecology and Obstetrics Center, The First Hospital of Jilin University, Changchun, China, Sun Yat-sen Memorial Hospital of SunYat-sen University, Guangzhou, China, Sun Yat-sen University Cancer Center Gansu Hospital, Guangzhou JOYO Pharma, China National Biotec Group,
Abstract
Response-adaptive resection following neoadjuvant penpulimab combined with chemotherapy in HPV-negative operable locally advanced head and neck squamous cell: A phase II clinical trial.Org: Cancer Center, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China, Union Hospital, Tongji Medical College Huazhong University of Science and Technology, Huazhong University of Science and Technology Union Shenzhen Hospital, Wuhan YZY Biopharma,
Abstract
Association of gut microbe and stress-related cancer metastasis and oleic acid degradation.Org: The Sixth Affiliated Hospital of Sun Yat-Sen, Guangzhou, China, Sun Yat-sen University Cancer Center Gansu Hospital, Guangzhou JOYO Pharma, China National Biotec Group, Sixth Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China,
Abstract
Immune checkpoint inhibitor retreatment in second-line treatment of esophageal cancer: A real-world study.Org: The First Affiliated Hospital of Henan University of Science and Technology, Luoyang Central Hospital affiliated to Zhengzhou University, China National Biotec Group, Department of Gastroenterology Oncology, The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, China,
Abstract
Phase I clinical study of FC084CSA, a high selective AXL kinase inhibitor that ameliorates tumor microenvironment and augments the effectivity of immunotherapy.Org: Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Shanghai Pulmonary Hospital, Shanghai, China, School of Medicine, Zhejiang University, Hangzhou, China, Tongji University School of Medicine, Shanghai Henlius Biotech,
Abstract
Integrating pathomics and radiomics for predicting survival among patients with intrahepatic cholangiocarcinoma undergoing surgical resection.Org: Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, The First Affiliated Hospital of USTC, Anhui Provincial Hospital, Hefei, China, Zhejiang University School of Medicine, Hangzhou Yirui Pharmaceutical Technology, China National Biotec Group,
Abstract
Phase I safety and preliminary efficacy of PM1009, a bispecific antibody targeting TIGIT and PVRIG, in patients with advanced solid tumors.Org: Shanghai East Hospital, Tongji University, Shanghai, China, School of Medicine, Zhejiang University, Hangzhou, China, Tongji University School of Medicine, Shanghai Henlius Biotech, China National Biotec Group,
Abstract
Predictive value of C reactive protein (CRP) and D-dimer in patients with advanced cervical cancer treated with sintilimab and anlotinib.Org: Department of Gynecology, Puyang Oilfield General Hospital, Puyang, China, Fujian Medical University Cancer Hospital, Fujian Cancer Hospital, Clinical Oncology School of Fujian Medical University, Fuzhou University,
Abstract
Phase 1 study of LB1410, a bivalent TIM-3/PD-1 bispecific antibody, in patients with advanced solid tumors or lymphoma.Org: Shanghai Henlius Biotech, China National Biotec Group,
Abstract
Effect of KDR mutations on efficacy of immune checkpoint inhibitors in patients with bladder cancer.Org: Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China, Jinan, Shandong Suncadia Medicine, China National Biotec Group, Jiangsu Simcere Diagnostics Co., Ltd., Nanjing Simcere Medical Laboratory Science Co., Ltd.,
Abstract
A phase Ib/II study of GFH018 in combination with toripalimab in recurrent/metastatic nasopharyngeal carcinoma (R/M NPC).Org: Sun Yat-sen University Cancer Center (China), Guangzhou, No, China National Biotec Group, Shanghai East Hospital, Tongji University, Shanghai, China, Tongji University School of Medicine,
Abstract
Low-dose fractionated radiotherapy combined with neoadjuvant chemotherapy for T3-4 nasopharyngeal carcinoma patients: Preliminary results of a phase II randomized controlled trial.Org: Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China, Sichuan Cancer Hospital and Institution, Sichuan Cancer Center, Radiation Oncology Key Laboratory of Sichuan Province, Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, School of Medicine, Zhejiang University, Hangzhou, China, University of Electronic Science and Technology of China,
Abstract
Safety and efficacy of transarterial chemoembolization combined with tyrosine kinase inhibitors and camrelizumab in the treatment of patients with advanced unresectable hepatocellular carcinoma.Org: Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Jinan, Shandong, China, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China National Biotec Group, Shandong Suncadia Medicine,
Abstract
Lenvatinib (LEN) combined with tislelizumab (TIS) plus transcatheter arterial chemoembolization (TACE) for unresectable hepatocellular carcinoma (uHCC): A single-arm, phase II clinical trial.Org: Guangxi Medical University Cancer Hospital, Nanning, China, China National Biotec Group, Nnanning,
Abstract
A phase 1 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of LB4330, a peptide fused to CLDN18.2 antibody targeting the tumor antigen associated CD8+t CELLS in patients with advanced solid tumors.Org: Shanghai Henlius Biotech, China National Biotec Group,
Abstract
Efficacy and safety of camrelizumab combined with chemotherapy versus chemotherapy alone as preoperative neoadjuvant therapy for resectable locally advanced esophageal squamous cell carcinoma: Preliminary results from a multicenter, prospective, randomized controlled study.Org: The First Affiliated Hospital of Anhui Medical University, Hefei, China National Biotec Group, Fuyang Cancer Hospital, Anqing Municipal Hospital,
Abstract
Influence of widely targeted quantitative lipidomics on plasma lipid predictors and pathway dysregulation for nasopharyngeal carcinoma.Org: Sun Yat-sen University Cancer Center Gansu Hospital, Guangzhou JOYO Pharma, China National Biotec Group,
Abstract
Induction therapy of toripalimab combined with docetaxel and cisplatin in locally advanced hypopharyngeal squamous cell carcinoma (HPSCC): A single-arm, phase II clinical trial.Org: Peking Union Medical College Hospital, Academy of Medical Sciences & Peking Union Medical College, Beijing, China, Beijing InnoCare Pharma Tech, China National Biotec Group,
Abstract
Sequential intravenous chemotherapy with drug-eluting bead bronchial arterial chemoembolization for the treatment of stages III and IV lung squamous cell carcinoma: A retrospective controlled clinical study.Org: The Fifth Affiliated Hospital of Wenzhou Medical College, Lishui Hospital, China National Biotec Group,
Abstract
Effectiveness and safety of camrelizumab in advanced esophageal cancer: A prospective multicenter observational cohort studies (ESCORT-RWS).Org: Peking University Cancer Hospital and Institute (Beijing Cancer Hospital), Beijing, China, Beijing InnoCare Pharma Tech, China National Biotec Group, Changzhi People's Hospital Affiliated to Changzhi Medical College, Changzhi City,
Abstract
Efficacy and safety of anlotinib combined with anthracycline and ifosfamide followed by anlotinib maintenance in advanced soft tissue sarcoma: A single-arm, phase 2 trial.Org: Rare Tumors Department, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Huaiyin District Jinan, China, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Jinan, Shandong, China, Shandong First Medical University and Shandong Academy of Medical Sciences, Huaiyin District Jinan, Jinan,
Abstract
A novel anti-HER2 monoclonal antibody IAH0968 in HER2-positive, heavily pretreated solid tumors: Results from a phase Ⅰa/Ⅰb, first-in-human, open-label, single-center study.Org: The First Hospital of China Medical University, Shenyang, China, Shenyang Sunshine Pharmaceutical, China National Biotec Group, he First Hospital of China Medical University,
Abstract
Development of allogenic nonviral RNA-based CAR-NK therapy targeting CDH17 in relapsed/refractory gastrointestinal cancer.Org: Arbele, Sha Tin, Hong Kong Sanatorium & Hospital, Shatin, Hong Kong, Medigen Biotechnology Corp.,
Abstract
Pretreatment radiomic biomarker for immunotherapy responder prediction in IB-IV stage NSCLC: A multi-center retrospective study.Org: Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China, Southern Medical University, Department of Thoracic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China, Department of Thoracic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China, Guangzhou, China, Geneseeq Research Institute, Nanjing Geneseeq Technology Inc., Nanjing, China, Nanfang Hospital, Southern Medical University, Guangzhou, China, Guangdong Provincial People's Hospital, Guangzhou JOYO Pharma,
Abstract
Utilize protein markers and genomic features for minimal residual disease detection in hepatocellular carcinoma.Org: Clinical Laboratories, Shenyou Bio, Zhengzhou Gensciences, China National Biotec Group, SeekIn Inc.,
Abstract
Clinical analysis of immunotherapy rechallenge in advanced gastric cancer.Org: Henan Cancer Hospital, China National Biotec Group, Zhengzhou Gensciences, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital,
Abstract
LATIFY: Phase 3 study of ceralasertib + durvalumab vs docetaxel in patients with locally advanced or metastatic non-small-cell lung cancer that progressed on or after anti-PD-(L)1 and platinum-based therapy.Org: Gustave Roussy Département d'Organisation du Parcours Patient, Villejuif, France, Cancer Institute of the State of São Paulo, São Paulo, Brazil, São Paulo, Brazil, Brazil,
Abstract
Amivantamab and lazertinib in treatment-naïve EGFR-mutated advanced non–small-cell lung cancer (NSCLC): Long-term follow-up and ctDNA results from CHRYSALIS.Org: Samsung Medical Center, Sungkyunkwan University School of Medicine, Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, SongDang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, South Korea, Yonsei Cancer Center, Yonsei University Health System, Yonsei University College of Medicine,
Abstract
High frequency of germline mutations in DDR associated genes SLX4, MSH6, CDK4, TSC2, and BRCA2 might contribute to the occurrence of MPLC.Org: The First People's Hospital of Foshan, Foshan First People's Hospital, China National Biotec Group, Jiangsu Simcere Diagnostics Co., Ltd., Nanjing Simcere Medical Laboratory Science Co., Ltd., The State Key Laboratory of Translational Medicine and Innovative Drug Development at Jiangsu Simcere Diagnostics Co. Ltd,
Abstract
Jaktinib in patients (pts) with myelofibrosis (MF) who were refractory to or relapsed after ruxolitinib: A single-arm, open-label, multicenter, phase 2 study.Org: Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, Winship Cancer Institute of Emory University, Atlanta, GA, Emory University, Atlanta, GA, Department of Biostatistics and Bioinformatics, Emory University, Atlanta, GA, Department of Medicine, Massachusetts General Hospital, Boston, MA, Department of Medicine, Emory University School of Medicine, Atlanta, GA, Department of Urology, Emory University School of Medicine, Atlanta, GA, The First Affiliated Hospital of USTC, Anhui Provincial Hospital, Hefei, China, Zhejiang University School of Medicine First Affiliated Hospital, Hangzhou, China, Hangzhou Yirui Pharmaceutical Technology, China National Biotec Group,
Abstract
Immunotherapy with or without radiotherapy in late-line treatment for metastatic esophageal cancer: A real-world study.Org: Department of Thoracic Oncology, NHO Kyushu Cancer Center, Fukuoka, Japan, Cancer Center, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China, West China Hospital, Sichuan University, Chengdu Origen Biotechnology,
Abstract
The impact of SARS-CoV2 Omicron variants epidemic on patients with cancer in China.Org: Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Tianjin Medical University General Hospital, Tianjin, China, Tianjin Hemay Pharmaceutical, China National Biotec Group,
Abstract
A retrospective study on the efficacy and safety of avatrombopag in the treatment of chemotherapy-induced thrombocytopenia in gastrointestinal cancer.Org: Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Sun Yat-sen University Cancer Center Gansu Hospital, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China, Collaborative Innovation Center for Cancer Medicine, Guangzhou JOYO Pharma,
Abstract
Treg cells and the response to neoadjuvant chemotherapy combined with immunotherapy in resectable esophageal squamous carcinoma.Org: The Third Affiliated Hospital of Soochow University, Changzhou, China, Changzhou Qianhong Bio-pharma, China National Biotec Group, Medical Department, 3D Medicines Inc.,
Abstract
Phase I study of anlotinib in pediatric patients with high-risk, recurrent, or refractory sarcomas.Org: Sun Yat-sen University Cancer Center Gansu Hospital, Guangzhou JOYO Pharma, China National Biotec Group,
Abstract
Effects of oncolytic bacteria, SGN1, against a broad spectrum of malignancies in pre-clinical and clinical studies.Org: Guangzhou Sinogen Pharmaceutical, Ltd, Guangzhou, China, Guangzhou JOYO Pharma, China National Biotec Group,
Abstract
Transarterial chemoembolization combined with camrelizumab and apatinib in the treatment of advanced hepatocellular carcinoma: Preoperative or postoperative combination? A prospective clinical study.Org: Fifth Medical Center of Chinese PLA General Hospital, Beijing InnoCare Pharma Tech, China National Biotec Group, Aerospace Medical Center, Aerospace Center Hospital,
Abstract
Therapeutic evaluation on Chinese calycosin decoction for chemoradiotherapy induced thrombocytopenia.Org: Jiangsu Health Vocational College, Nanjing Yoko Biomedical, China National Biotec Group, Liyang people‘s hospital, Jingling Hospital,
Abstract
Efficacy and safety analysis of immune checkpoint inhibitors plus angiogenesis inhibitors for treatment of advanced driver-negative NSCLC in elderly patients: A retrospective study.Org: The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Kintor Pharmaceutical, China National Biotec Group,
Abstract
The impact of DNA damage repair gene mutations on therapeutic response among Chinese patients diagnosed with advanced biliary tract cancer.Org: Gastric Cancer Center, Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, SongDang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, South Korea, Cancer Center, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China, Laboratory of Gastric Cancer, State Key Laboratory of Biotherapy,
Abstract
Predicting the immunotherapy response based on molecular subtypes of pan-immune signatures in gastrointestinal stromal tumor.Org: ChosenMed Technology (Zhejiang) Co., Ltd., Beijing InnoCare Pharma Tech, China National Biotec Group,
Abstract
Efficacy and safety of penpulimab-containing regimens for advanced malignant solid tumors that have failed immunotherapy: A real-world study.Org: First Affiliated Hospital of Soochow University, Suzhou Kintor Pharmaceutical, China National Biotec Group,
Abstract
Phase I/II study to evaluate penpulimab combined with anlotinib and epirubicin in the first-line treatment of soft tissue sarcoma: Updated.Org: Liver Cancer Institute and Zhongshan Hospital, Fudan University, Shanghai, China, Zhongshan Hospital of Fudan University, Shanghai, China, Fudan University (Xiamen Branch), Shanghai Henlius Biotech, China National Biotec Group,
Abstract
Phase I clinical trial using a unique immunotherapeutic combination of MUC1-targeted CAR-T cells with PD-1-knockout in the treatment of patients with advanced esophageal cancer.Org: First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou JOYO Pharma, Guangdong Ruishun Biotech, China National Biotec Group,
Abstract
Efficacy and safety of regorafenib plus biweekly TAS-102 for refractory metastatic colorectal cancer (REGTAS): A multicenter single-arm phase II trial.Org: Qilu Hospital of Shandong University, Jinan, China National Biotec Group, Linyi Cancer Hospital, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China,
Abstract
A retrospective real-world study of nimotuzumab combined with chemotherapy for advanced pancreatic cancer.Org: First Affiliated Hospital of Medical College of Xi’an Jiaotong University, Xi'an, China, Xi'an, shaanxi, China, China National Biotec Group,
Abstract
Influence of high COL19A1 expression on the effectiveness of neoadjuvant immunotherapy plus chemotherapy and long-term survival in patients with esophageal squamous cell carcinoma.Org: Guangdong Provincial People's Hospital, Guangzhou JOYO Pharma, China National Biotec Group, Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China,
Abstract
A combination of niraparib plus anlotinib in patients with platinum-resistant ovarian clear cell carcinoma: Results of a single-arm phase II study (CC-ANNIE study).Org: Sun Yat-Sen Memorial Hospital, Guangzhou JOYO Pharma, China National Biotec Group, Department of Radiology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China, Sun Yat-sen Memorial Hospital of SunYat-sen University, Guangzhou, China,
Abstract
Oxaliplatin based chemotherapy for advanced well-differentiated neuroendocrine tumors: A systematic review and meta-analysis.Org: Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Qilu Hospital of Shandong University, Jinan, China National Biotec Group,
Abstract
Platelet decline rate as the indication of using recombinant human thrombopoietin to prevent chemotherapy induced thrombocytopenia: A prospective, randomized, controlled study.Org: Union Hospital, Tongji Medical College Huazhong University of Science and Technology, Huazhong University of Science and Technology Union Shenzhen Hospital, Whhan, China National Biotec Group,
Abstract
Hepatic arterial infusion chemotherapy (HAIC) combined with tislelizumab and lenvatinib for advanced hepatocellular carcinoma (aHCC) with Vp3-4 portal vein tumor thrombosis (PVTT): A single-arm, phase II study.Org: The Second Affiliated Hospital Of Nanchang University, Nanchang, China National Biotec Group,
Abstract
CD73/adenosine pathway-related gene signature for intratumor heterogeneity and immune infiltration in prognosis of lung adenocarcinoma.Org: Nanfang Hospital Zengcheng Campus Respiratory Department, Guangzhou JOYO Pharma, China National Biotec Group,
Abstract
Characteristics and trends of globally registered malignant pleural mesothelioma clinical trials in the past 27 years.Org: Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangdong Pharmaceutical University, Guangzhou, China, Guangdong Provincial People's Hospital,
Abstract
A phase Ⅰ/Ⅱa study of cetuximab combined with fruquintinib in the previously treated RAS/BRAF wild-type metastatic colorectal cancer: Results of the CEFRU study.Org: Traditional Chinese Medicine Hospital of Guangdong Province, Guangzhou JOYO Pharma, China National Biotec Group, Guangdong Provincial Hospital of Chinese Medicine Breast Center, Guangdong Provincial People's Hospital,
Abstract
BIOMARKER CHANGES IN TAKAYASU ARTERITIS AFTER TOFACITINIB TREATMENT AND THE MOLECULAR SIGNATURE ASSOCIATED WITH DISEASE CHARACTERISTICSOrg: Zhongshan Hospital of Fudan University, Shanghai, China, Fudan University (Xiamen Branch), Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University, Düsseldorf, Germany, Shanghai Henlius Biotech, China National Biotec Group,
Abstract
ASSOCIATION OF HEALTHY LIFESTYLES WITH ALL-CAUSE AND CAUSE-SPECIFIC MORTALITY AMONG INDIVIDUALS WITH OSTEOARTHRITIS: A PROSPECTIVE COHORT STUDY OF THE UK BIOBANKOrg: Zhujiang Hospital, Southern Medical University, Clinical Research Centre, Guangzhou JOYO Pharma, China National Biotec Group,